{"product_id":"hexarelin-10mg-vial","title":"Hexarelin 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                      \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"43\" data-end=\"596\"\u003e\u003cstrong\u003eHexarelin \u003c\/strong\u003eis a synthetic \u003cstrong data-start=\"101\" data-end=\"138\"\u003egrowth-hormone secretagogue (GHS)\u003c\/strong\u003e and \u003cstrong data-start=\"143\" data-end=\"181\"\u003eghrelin-receptor (GHSR-1a) agonist\u003c\/strong\u003e from the GHRP family (hexapeptide). It provokes \u003cstrong data-start=\"230\" data-end=\"261\"\u003erapid, pulsatile GH release\u003c\/strong\u003e from pituitary somatotrophs and acts within the hypothalamus. Beyond GHSR-1a, hexarelin also interacts with \u003cstrong data-start=\"370\" data-end=\"378\"\u003eCD36\u003c\/strong\u003e on cardiovascular and immune cells—supporting \u003cstrong data-start=\"425\" data-end=\"468\"\u003eGH-independent cardioprotective effects\u003c\/strong\u003e described in preclinical models. It is \u003cstrong data-start=\"508\" data-end=\"532\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e for therapy; research and compounded use exist in some markets.\u003c\/p\u003e\n\u003chr data-start=\"598\" data-end=\"601\"\u003e\n\u003ch3 data-start=\"603\" data-end=\"663\"\u003eAdditional Benefits of Hexarelin Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"665\" data-end=\"3066\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"665\" data-end=\"693\"\u003e\n\u003ctr data-start=\"665\" data-end=\"693\"\u003e\n\u003cth data-start=\"665\" data-end=\"675\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"675\" data-end=\"693\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"704\" data-end=\"3066\"\u003e\n\u003ctr data-start=\"704\" data-end=\"996\"\u003e\n\u003ctd data-start=\"704\" data-end=\"739\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"706\" data-end=\"738\"\u003e1 Physiologic GH pulsatility\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"739\" data-end=\"996\" data-col-size=\"xl\"\u003eSC or intranasal hexarelin elicits \u003cstrong data-start=\"776\" data-end=\"794\"\u003ebrief GH peaks\u003c\/strong\u003e and modest \u003cstrong data-start=\"806\" data-end=\"821\"\u003eIGF-1 rises\u003c\/strong\u003e while preserving hypothalamic–pituitary feedback; synergy with \u003cstrong data-start=\"885\" data-end=\"893\"\u003eGHRH\u003c\/strong\u003e is well documented. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Endocrinology \u0026amp; Metabolism; Neuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"997\" data-end=\"1335\"\u003e\n\u003ctd data-start=\"997\" data-end=\"1050\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"999\" data-end=\"1049\"\u003e2 Cardioprotection (I\/R and pressure overload)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1050\" data-end=\"1335\" data-col-size=\"xl\"\u003eIn rodent infarction and pressure-overload models, hexarelin \u003cstrong data-start=\"1113\" data-end=\"1137\"\u003ereduces infarct size\u003c\/strong\u003e, \u003cstrong data-start=\"1139\" data-end=\"1156\"\u003eimproves LVEF\u003c\/strong\u003e, and limits apoptosis—effects partially \u003cstrong data-start=\"1197\" data-end=\"1224\"\u003eindependent of GH\/IGF-1\u003c\/strong\u003e and linked to \u003cstrong data-start=\"1239\" data-end=\"1261\"\u003eCD36–PI3K–Akt–eNOS\u003c\/strong\u003e signalling. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Circulation Research; Cardiovascular Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1336\" data-end=\"1612\"\u003e\n\u003ctd data-start=\"1336\" data-end=\"1378\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1338\" data-end=\"1377\"\u003e3 Anti-fibrotic cardiac remodelling\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1378\" data-end=\"1612\" data-col-size=\"xl\"\u003eChronic dosing \u003cstrong data-start=\"1395\" data-end=\"1429\"\u003eattenuates myocardial fibrosis\u003c\/strong\u003e and hypertrophy markers (e.g., collagen I\/III, TGF-β), improving diastolic indices. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Molecular and Cellular Cardiology; American Journal of Physiology–Heart\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1613\" data-end=\"1880\"\u003e\n\u003ctd data-start=\"1613\" data-end=\"1661\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1615\" data-end=\"1660\"\u003e4 Appetite \u0026amp; body-composition in cachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1661\" data-end=\"1880\" data-col-size=\"xl\"\u003eAs a ghrelin mimetic, hexarelin \u003cstrong data-start=\"1695\" data-end=\"1734\"\u003eincreases hunger and caloric intake\u003c\/strong\u003e; small studies and models show \u003cstrong data-start=\"1766\" data-end=\"1797\"\u003elean-mass preservation\/gain\u003c\/strong\u003e under catabolic conditions. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Nutrition; Annals of Oncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1881\" data-end=\"2163\"\u003e\n\u003ctd data-start=\"1881\" data-end=\"1921\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1883\" data-end=\"1920\"\u003e5 Anti-atrophy in skeletal muscle\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1921\" data-end=\"2163\" data-col-size=\"xl\"\u003eHind-limb unloading and denervation models demonstrate \u003cstrong data-start=\"1978\" data-end=\"2001\"\u003epreserved fibre CSA\u003c\/strong\u003e and \u003cstrong data-start=\"2006\" data-end=\"2047\"\u003ehigher myofibrillar protein synthesis\u003c\/strong\u003e, via GH\/IGF-1 plus local GHSR effects. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Muscle \u0026amp; Nerve; American Journal of Physiology–Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2164\" data-end=\"2381\"\u003e\n\u003ctd data-start=\"2164\" data-end=\"2194\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2166\" data-end=\"2193\"\u003e6 Bone-turnover support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2194\" data-end=\"2381\" data-col-size=\"xl\"\u003eOvariectomised-rat data show \u003cstrong data-start=\"2225\" data-end=\"2263\"\u003e↑ osteocalcin\/alkaline phosphatase\u003c\/strong\u003e and modest \u003cstrong data-start=\"2275\" data-end=\"2288\"\u003eBMD gains\u003c\/strong\u003e, consistent with GH\/IGF-1-mediated anabolism. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Bone; Journal of Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2382\" data-end=\"2606\"\u003e\n\u003ctd data-start=\"2382\" data-end=\"2421\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2384\" data-end=\"2420\"\u003e7 Sleep-architecture enhancement\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2421\" data-end=\"2606\" data-col-size=\"xl\"\u003eBedtime administration \u003cstrong data-start=\"2446\" data-end=\"2480\"\u003eaugments slow-wave sleep (SWS)\u003c\/strong\u003e and nocturnal GH pulses, with exploratory improvements in next-day cognition. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sleep; Psychoneuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2607\" data-end=\"2820\"\u003e\n\u003ctd data-start=\"2607\" data-end=\"2645\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2609\" data-end=\"2644\"\u003e8 GI mucosal protection\/healing\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2645\" data-end=\"2820\" data-col-size=\"xl\"\u003eGHSR activation promotes \u003cstrong data-start=\"2672\" data-end=\"2707\"\u003eangiogenesis and anti-apoptosis\u003c\/strong\u003e in gastric\/colonic injury models, accelerating ulcer closure. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Gut; American Journal of Pathology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2821\" data-end=\"3066\"\u003e\n\u003ctd data-start=\"2821\" data-end=\"2862\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2823\" data-end=\"2861\"\u003e9 Endothelial function \u0026amp; perfusion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2862\" data-end=\"3066\" data-col-size=\"xl\"\u003eAcute dosing \u003cstrong data-start=\"2877\" data-end=\"2924\"\u003eenhances endothelium-dependent vasodilation\u003c\/strong\u003e and microvascular perfusion in preclinical systems, aligning with \u003cstrong data-start=\"2991\" data-end=\"2999\"\u003eeNOS\u003c\/strong\u003e activation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Vascular Pharmacology; Atherosclerosis\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3068\" data-end=\"3071\"\u003e\n\u003ch2 data-start=\"3073\" data-end=\"3108\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3110\" data-end=\"3145\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-start=\"3146\" data-end=\"3473\"\u003eHexarelin binds \u003cstrong data-start=\"3162\" data-end=\"3173\"\u003eGHSR-1a\u003c\/strong\u003e (GPCR) on hypothalamic neurons and pituitary somatotrophs → \u003cstrong data-start=\"3234\" data-end=\"3257\"\u003eGαq\/11–PLC–IP₃\/Ca²⁺\u003c\/strong\u003ecascade → GH vesicle exocytosis. It \u003cstrong data-start=\"3294\" data-end=\"3318\"\u003esynergises with GHRH\u003c\/strong\u003e and is \u003cstrong data-start=\"3326\" data-end=\"3362\"\u003epartly inhibited by somatostatin\u003c\/strong\u003e. Cardiovascular actions additionally involve \u003cstrong data-start=\"3408\" data-end=\"3416\"\u003eCD36\u003c\/strong\u003e, providing \u003cstrong data-start=\"3428\" data-end=\"3446\"\u003eGH-independent\u003c\/strong\u003e cytoprotective signalling.\u003c\/p\u003e\n\u003ch3 data-start=\"3475\" data-end=\"3502\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3504\" data-end=\"3830\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3504\" data-end=\"3546\"\u003e\n\u003ctr data-start=\"3504\" data-end=\"3546\"\u003e\n\u003cth data-start=\"3504\" data-end=\"3514\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3514\" data-end=\"3535\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3535\" data-end=\"3546\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3561\" data-end=\"3830\"\u003e\n\u003ctr data-start=\"3561\" data-end=\"3653\"\u003e\n\u003ctd data-start=\"3561\" data-end=\"3583\" data-col-size=\"sm\"\u003eGH → GHR–JAK2–STAT5\u003c\/td\u003e\n\u003ctd data-start=\"3583\" data-end=\"3627\" data-col-size=\"md\"\u003e↑ IGF-1, ↑ lipolysis, ↑ protein synthesis\u003c\/td\u003e\n\u003ctd data-start=\"3627\" data-end=\"3653\" data-col-size=\"sm\"\u003eLiver, adipose, muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3654\" data-end=\"3733\"\u003e\n\u003ctd data-start=\"3654\" data-end=\"3675\" data-col-size=\"sm\"\u003eGHSR-AMPK\/NPY-AgRP\u003c\/td\u003e\n\u003ctd data-start=\"3675\" data-end=\"3708\" data-col-size=\"md\"\u003e↑ appetite, ↑ gastric motility\u003c\/td\u003e\n\u003ctd data-start=\"3708\" data-end=\"3733\" data-col-size=\"sm\"\u003eHypothalamus\/GI tract\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3734\" data-end=\"3830\"\u003e\n\u003ctd data-start=\"3734\" data-end=\"3757\" data-col-size=\"sm\"\u003eCD36 → PI3K–Akt–eNOS\u003c\/td\u003e\n\u003ctd data-start=\"3757\" data-end=\"3803\" data-col-size=\"md\"\u003eAnti-apoptotic, anti-fibrotic, vasodilatory\u003c\/td\u003e\n\u003ctd data-start=\"3803\" data-end=\"3830\" data-col-size=\"sm\"\u003eMyocardium, endothelium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3832\" data-end=\"3835\"\u003e\n\u003ch2 data-start=\"3837\" data-end=\"3859\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"3861\" data-end=\"4275\"\u003e\n\u003cli data-start=\"3861\" data-end=\"3956\"\u003e\n\u003cp data-start=\"3863\" data-end=\"3956\"\u003e\u003cstrong data-start=\"3863\" data-end=\"3885\"\u003eAbsorption\/routes:\u003c\/strong\u003e \u003cstrong data-start=\"3886\" data-end=\"3920\"\u003eSC, IV, intranasal, sublingual\u003c\/strong\u003e; oral bioavailability negligible.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3957\" data-end=\"4044\"\u003e\n\u003cp data-start=\"3959\" data-end=\"4044\"\u003e\u003cstrong data-start=\"3959\" data-end=\"3974\"\u003eOnset\/peak:\u003c\/strong\u003e GH peaks \u003cstrong data-start=\"3984\" data-end=\"3998\"\u003e~15–30 min\u003c\/strong\u003e post-dose; returns to baseline by \u003cstrong data-start=\"4033\" data-end=\"4041\"\u003e~2 h\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4045\" data-end=\"4176\"\u003e\n\u003cp data-start=\"4047\" data-end=\"4176\"\u003e\u003cstrong data-start=\"4047\" data-end=\"4061\"\u003eHalf-life:\u003c\/strong\u003e Short plasma \u003cstrong data-start=\"4075\" data-end=\"4092\"\u003et½ ~10–30 min\u003c\/strong\u003e; pharmacodynamic impact persists via \u003cstrong data-start=\"4130\" data-end=\"4139\"\u003eIGF-1\u003c\/strong\u003e accumulation with repeated pulses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4177\" data-end=\"4275\"\u003e\n\u003cp data-start=\"4179\" data-end=\"4275\"\u003e\u003cstrong data-start=\"4179\" data-end=\"4193\"\u003eClearance:\u003c\/strong\u003e Peptidase degradation; renal\/hepatic peptide catabolism; \u003cstrong data-start=\"4251\" data-end=\"4261\"\u003eno CYP\u003c\/strong\u003e interactions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4277\" data-end=\"4280\"\u003e\n\u003ch2 data-start=\"4282\" data-end=\"4327\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4329\" data-end=\"4360\"\u003e4.1 Endocrine \u0026amp; Metabolic\u003c\/h3\u003e\n\u003cp data-start=\"4361\" data-end=\"4583\"\u003eIn healthy adults and GH-deficient cohorts, hexarelin provokes \u003cstrong data-start=\"4424\" data-end=\"4447\"\u003erobust GH responses\u003c\/strong\u003e (often \u0026gt; GHRP-6) with \u003cstrong data-start=\"4470\" data-end=\"4496\"\u003emodest IGF-1 increases\u003c\/strong\u003e over days; \u003cstrong data-start=\"4508\" data-end=\"4525\"\u003etachyphylaxis\u003c\/strong\u003e of GH peaks can occur with high-frequency chronic dosing.\u003c\/p\u003e\n\u003ch3 data-start=\"4585\" data-end=\"4621\"\u003e4.2 Cardiovascular Remodelling\u003c\/h3\u003e\n\u003cp data-start=\"4622\" data-end=\"4885\"\u003eAcross infarction, reperfusion, and pressure-overload models, hexarelin improves \u003cstrong data-start=\"4703\" data-end=\"4734\"\u003esystolic\/diastolic function\u003c\/strong\u003e, reduces \u003cstrong data-start=\"4744\" data-end=\"4770\"\u003eapoptosis and fibrosis\u003c\/strong\u003e, and enhances \u003cstrong data-start=\"4785\" data-end=\"4818\"\u003ecoronary\/endothelial function\u003c\/strong\u003e—partly \u003cstrong data-start=\"4826\" data-end=\"4853\"\u003eindependent of GH\/IGF-1\u003c\/strong\u003e via \u003cstrong data-start=\"4858\" data-end=\"4875\"\u003eCD36–Akt–eNOS\u003c\/strong\u003e pathways.\u003c\/p\u003e\n\u003ch3 data-start=\"4887\" data-end=\"4910\"\u003e4.3 Muscle \u0026amp; Bone\u003c\/h3\u003e\n\u003cp data-start=\"4911\" data-end=\"5073\"\u003eModels of disuse and denervation show \u003cstrong data-start=\"4949\" data-end=\"4965\"\u003eanti-atrophy\u003c\/strong\u003e effects and faster recovery; bone studies suggest \u003cstrong data-start=\"5016\" data-end=\"5037\"\u003eanabolic turnover\u003c\/strong\u003econsistent with GH-axis activation.\u003c\/p\u003e\n\u003ch3 data-start=\"5075\" data-end=\"5108\"\u003e4.4 Sleep, Appetite, and GI\u003c\/h3\u003e\n\u003cp data-start=\"5109\" data-end=\"5249\"\u003eNight dosing \u003cstrong data-start=\"5122\" data-end=\"5139\"\u003eincreases SWS\u003c\/strong\u003e and appetite; GI mucosal studies demonstrate \u003cstrong data-start=\"5185\" data-end=\"5208\"\u003eaccelerated healing\u003c\/strong\u003e under inflammatory or ulcerative injury.\u003c\/p\u003e\n\u003chr data-start=\"5251\" data-end=\"5254\"\u003e\n\u003ch2 data-start=\"5256\" data-end=\"5289\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5291\" data-end=\"5791\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5291\" data-end=\"5329\"\u003e\n\u003ctr data-start=\"5291\" data-end=\"5329\"\u003e\n\u003cth data-start=\"5291\" data-end=\"5299\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5299\" data-end=\"5311\" data-col-size=\"sm\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5311\" data-end=\"5329\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5344\" data-end=\"5791\"\u003e\n\u003ctr data-start=\"5344\" data-end=\"5429\"\u003e\n\u003ctd data-start=\"5344\" data-end=\"5371\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5346\" data-end=\"5370\"\u003eCancer\/COPD cachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5371\" data-end=\"5406\" data-col-size=\"sm\"\u003eOrexigenic + GH-anabolic synergy\u003c\/td\u003e\n\u003ctd data-start=\"5406\" data-end=\"5429\" data-col-size=\"sm\"\u003eEarly trials\/pilots\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5430\" data-end=\"5532\"\u003e\n\u003ctd data-start=\"5430\" data-end=\"5467\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5432\" data-end=\"5466\"\u003eCardio-protection (post-MI\/HF)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5467\" data-end=\"5503\" data-col-size=\"sm\"\u003eCD36\/GHSR-mediated cytoprotection\u003c\/td\u003e\n\u003ctd data-start=\"5503\" data-end=\"5532\" data-col-size=\"sm\"\u003eTranslational\/preclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5533\" data-end=\"5612\"\u003e\n\u003ctd data-start=\"5533\" data-end=\"5558\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5535\" data-end=\"5557\"\u003eSarcopenic obesity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5558\" data-end=\"5597\" data-col-size=\"sm\"\u003eGH pulses with limited chronic IGF-1\u003c\/td\u003e\n\u003ctd data-start=\"5597\" data-end=\"5612\" data-col-size=\"sm\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5613\" data-end=\"5688\"\u003e\n\u003ctd data-start=\"5613\" data-end=\"5649\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5615\" data-end=\"5648\"\u003eSleep SWS decline in mid-life\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5649\" data-end=\"5668\" data-col-size=\"sm\"\u003eAugment SWS \u0026amp; GH\u003c\/td\u003e\n\u003ctd data-start=\"5668\" data-end=\"5688\" data-col-size=\"sm\"\u003eProof-of-concept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5689\" data-end=\"5791\"\u003e\n\u003ctd data-start=\"5689\" data-end=\"5723\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5691\" data-end=\"5722\"\u003eCritical-illness catabolism\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5723\" data-end=\"5764\" data-col-size=\"sm\"\u003eAnti-atrophy and GI mucosal protection\u003c\/td\u003e\n\u003ctd data-start=\"5764\" data-end=\"5791\" data-col-size=\"sm\"\u003ePreclinical\/feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5793\" data-end=\"5796\"\u003e\n\u003ch2 data-start=\"5798\" data-end=\"5827\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"5829\" data-end=\"6515\"\u003e\n\u003cli data-start=\"5829\" data-end=\"5948\"\u003e\n\u003cp data-start=\"5831\" data-end=\"5948\"\u003e\u003cstrong data-start=\"5831\" data-end=\"5842\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-start=\"5843\" data-end=\"5855\"\u003eFlushing\u003c\/strong\u003e, \u003cstrong data-start=\"5857\" data-end=\"5873\"\u003eparesthesias\u003c\/strong\u003e, \u003cstrong data-start=\"5875\" data-end=\"5895\"\u003etransient hunger\u003c\/strong\u003e, \u003cstrong data-start=\"5897\" data-end=\"5909\"\u003eheadache\u003c\/strong\u003e, mild \u003cstrong data-start=\"5916\" data-end=\"5945\"\u003einjection-site irritation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5949\" data-end=\"6058\"\u003e\n\u003cp data-start=\"5951\" data-end=\"6058\"\u003e\u003cstrong data-start=\"5951\" data-end=\"5971\"\u003eEndocrine drift:\u003c\/strong\u003e Short-lived rises in \u003cstrong data-start=\"5993\" data-end=\"6006\"\u003eprolactin\u003c\/strong\u003e and \u003cstrong data-start=\"6011\" data-end=\"6028\"\u003eACTH\/cortisol\u003c\/strong\u003e around 30–60 min post-dose.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6059\" data-end=\"6152\"\u003e\n\u003cp data-start=\"6061\" data-end=\"6152\"\u003e\u003cstrong data-start=\"6061\" data-end=\"6075\"\u003eGlycaemia:\u003c\/strong\u003e Possible \u003cstrong data-start=\"6085\" data-end=\"6118\"\u003emild fasting-glucose increase\u003c\/strong\u003e; monitor in insulin resistance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6153\" data-end=\"6251\"\u003e\n\u003cp data-start=\"6155\" data-end=\"6251\"\u003e\u003cstrong data-start=\"6155\" data-end=\"6162\"\u003eCV:\u003c\/strong\u003e Generally favourable signals preclinically; rare \u003cstrong data-start=\"6212\" data-end=\"6228\"\u003epalpitations\u003c\/strong\u003e reported clinically.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6252\" data-end=\"6392\"\u003e\n\u003cp data-start=\"6254\" data-end=\"6392\"\u003e\u003cstrong data-start=\"6254\" data-end=\"6272\"\u003eTachyphylaxis:\u003c\/strong\u003e GH responses may \u003cstrong data-start=\"6290\" data-end=\"6303\"\u003eattenuate\u003c\/strong\u003e with frequent long-term dosing; intermittent schedules are often explored in research.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6393\" data-end=\"6515\"\u003e\n\u003cp data-start=\"6395\" data-end=\"6515\"\u003e\u003cstrong data-start=\"6395\" data-end=\"6426\"\u003eContraindications\/cautions:\u003c\/strong\u003e Active malignancy under anabolic-sensitive evaluation, uncontrolled diabetes, pregnancy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6517\" data-end=\"6546\"\u003e\u003cstrong data-start=\"6517\" data-end=\"6546\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6548\" data-end=\"6980\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6548\" data-end=\"6635\"\u003e\n\u003ctr data-start=\"6548\" data-end=\"6635\"\u003e\n\u003cth data-start=\"6548\" data-end=\"6558\" data-col-size=\"sm\"\u003eConcern\u003c\/th\u003e\n\u003cth data-start=\"6558\" data-end=\"6574\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6560\" data-end=\"6573\"\u003eHexarelin\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6574\" data-end=\"6601\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6576\" data-end=\"6600\"\u003eGHRP-2 (pralmorelin)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6601\" data-end=\"6635\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6603\" data-end=\"6633\"\u003eMK-677 (oral GHSR agonist)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6654\" data-end=\"6980\"\u003e\n\u003ctr data-start=\"6654\" data-end=\"6745\"\u003e\n\u003ctd data-start=\"6654\" data-end=\"6672\" data-col-size=\"sm\"\u003eIGF-1 elevation\u003c\/td\u003e\n\u003ctd data-start=\"6672\" data-end=\"6698\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6674\" data-end=\"6697\"\u003eModerate, pulsatile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6698\" data-end=\"6720\" data-col-size=\"sm\"\u003eModerate, pulsatile\u003c\/td\u003e\n\u003ctd data-start=\"6720\" data-end=\"6745\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6722\" data-end=\"6743\"\u003eHigher, sustained\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6746\" data-end=\"6809\"\u003e\n\u003ctd data-start=\"6746\" data-end=\"6764\" data-col-size=\"sm\"\u003eAppetite impact\u003c\/td\u003e\n\u003ctd data-start=\"6764\" data-end=\"6799\" data-col-size=\"sm\"\u003e\n\u003cstrong data-start=\"6766\" data-end=\"6771\"\u003e↑\u003c\/strong\u003e (less than ghrelin\/GHRP-6)\u003c\/td\u003e\n\u003ctd data-start=\"6799\" data-end=\"6804\" data-col-size=\"sm\"\u003e↑↑\u003c\/td\u003e\n\u003ctd data-start=\"6804\" data-end=\"6809\" data-col-size=\"sm\"\u003e↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6810\" data-end=\"6884\"\u003e\n\u003ctd data-start=\"6810\" data-end=\"6837\" data-col-size=\"sm\"\u003eProlactin\/cortisol spike\u003c\/td\u003e\n\u003ctd data-start=\"6837\" data-end=\"6859\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6839\" data-end=\"6858\"\u003eYes (transient)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6859\" data-end=\"6877\" data-col-size=\"sm\"\u003eYes (transient)\u003c\/td\u003e\n\u003ctd data-start=\"6877\" data-end=\"6884\" data-col-size=\"sm\"\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6885\" data-end=\"6937\"\u003e\n\u003ctd data-start=\"6885\" data-end=\"6901\" data-col-size=\"sm\"\u003eGlucose drift\u003c\/td\u003e\n\u003ctd data-start=\"6901\" data-end=\"6910\" data-col-size=\"sm\"\u003eMild ↑\u003c\/td\u003e\n\u003ctd data-start=\"6910\" data-end=\"6919\" data-col-size=\"sm\"\u003eMild ↑\u003c\/td\u003e\n\u003ctd data-start=\"6919\" data-end=\"6937\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6921\" data-end=\"6935\"\u003eModerate ↑\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6938\" data-end=\"6980\"\u003e\n\u003ctd data-start=\"6938\" data-end=\"6947\" data-col-size=\"sm\"\u003eRoutes\u003c\/td\u003e\n\u003ctd data-start=\"6947\" data-end=\"6961\" data-col-size=\"sm\"\u003eSC\/IV\/IN\/SL\u003c\/td\u003e\n\u003ctd data-start=\"6961\" data-end=\"6972\" data-col-size=\"sm\"\u003eIV\/SC\/IN\u003c\/td\u003e\n\u003ctd data-start=\"6972\" data-end=\"6980\" data-col-size=\"sm\"\u003eOral\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6982\" data-end=\"6985\"\u003e\n\u003ch2 data-start=\"6987\" data-end=\"7013\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7015\" data-end=\"7341\"\u003e\n\u003cli data-start=\"7015\" data-end=\"7072\"\u003e\n\u003cp data-start=\"7017\" data-end=\"7072\"\u003e\u003cstrong data-start=\"7017\" data-end=\"7043\"\u003eTherapeutic approvals:\u003c\/strong\u003e \u003cstrong data-start=\"7044\" data-end=\"7052\"\u003eNone\u003c\/strong\u003e in major markets.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7073\" data-end=\"7173\"\u003e\n\u003cp data-start=\"7075\" data-end=\"7173\"\u003e\u003cstrong data-start=\"7075\" data-end=\"7091\"\u003eDiagnostics:\u003c\/strong\u003e Unlike GHRP-2 (approved in Japan), \u003cstrong data-start=\"7127\" data-end=\"7170\"\u003ehexarelin is not an approved diagnostic\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7174\" data-end=\"7261\"\u003e\n\u003cp data-start=\"7176\" data-end=\"7261\"\u003e\u003cstrong data-start=\"7176\" data-end=\"7186\"\u003eSport:\u003c\/strong\u003e Classified as a \u003cstrong data-start=\"7203\" data-end=\"7246\"\u003eprohibited peptide hormone\/secretagogue\u003c\/strong\u003e by \u003cstrong data-start=\"7250\" data-end=\"7258\"\u003eWADA\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7262\" data-end=\"7341\"\u003e\n\u003cp data-start=\"7264\" data-end=\"7341\"\u003e\u003cstrong data-start=\"7264\" data-end=\"7275\"\u003eAccess:\u003c\/strong\u003e Research-use or compounded products; \u003cstrong data-start=\"7313\" data-end=\"7340\"\u003equality and purity vary\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7343\" data-end=\"7346\"\u003e\n\u003ch2 data-start=\"7348\" data-end=\"7371\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7373\" data-end=\"8004\"\u003e\n\u003cli data-start=\"7373\" data-end=\"7554\"\u003e\n\u003cp data-start=\"7375\" data-end=\"7554\"\u003e\u003cstrong data-start=\"7375\" data-end=\"7406\"\u003eCardio-focused development:\u003c\/strong\u003e Human studies targeting \u003cstrong data-start=\"7431\" data-end=\"7454\"\u003epost-MI remodelling\u003c\/strong\u003e and \u003cstrong data-start=\"7459\" data-end=\"7474\"\u003eHFpEF\/HFrEF\u003c\/strong\u003e with mechanistic endpoints (strain imaging, NT-proBNP, endothelial function).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7555\" data-end=\"7658\"\u003e\n\u003cp data-start=\"7557\" data-end=\"7658\"\u003e\u003cstrong data-start=\"7557\" data-end=\"7576\"\u003ePK engineering:\u003c\/strong\u003e \u003cstrong data-start=\"7577\" data-end=\"7599\"\u003eLipidated or depot\u003c\/strong\u003e analogs to extend half-life and reduce dosing frequency.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7659\" data-end=\"7846\"\u003e\n\u003cp data-start=\"7661\" data-end=\"7846\"\u003e\u003cstrong data-start=\"7661\" data-end=\"7686\"\u003eCombination regimens:\u003c\/strong\u003e Pair with \u003cstrong data-start=\"7697\" data-end=\"7720\"\u003eresistance exercise\u003c\/strong\u003e, \u003cstrong data-start=\"7722\" data-end=\"7743\"\u003enutrition therapy\u003c\/strong\u003e, or \u003cstrong data-start=\"7748\" data-end=\"7773\"\u003eanti-catabolic agents\u003c\/strong\u003e in cachexia; evaluate co-therapy with \u003cstrong data-start=\"7812\" data-end=\"7823\"\u003eGLP-1RA\u003c\/strong\u003e to temper orexigeny.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7847\" data-end=\"8004\"\u003e\n\u003cp data-start=\"7849\" data-end=\"8004\"\u003e\u003cstrong data-start=\"7849\" data-end=\"7877\"\u003eBiomarker-guided dosing:\u003c\/strong\u003e Track \u003cstrong data-start=\"7884\" data-end=\"7897\"\u003eIGF-1 SDS\u003c\/strong\u003e, \u003cstrong data-start=\"7899\" data-end=\"7914\"\u003eGH profiles\u003c\/strong\u003e, and \u003cstrong data-start=\"7920\" data-end=\"7927\"\u003eCGM\u003c\/strong\u003e for glycaemic safety; explore \u003cstrong data-start=\"7958\" data-end=\"7984\"\u003eCD36-linked biomarkers\u003c\/strong\u003e for cardiac trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8006\" data-end=\"8009\"\u003e\n\u003ch3 data-start=\"8011\" data-end=\"8034\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8036\" data-end=\"9042\"\u003e\n\u003cli data-start=\"8036\" data-end=\"8160\"\u003e\n\u003cp data-start=\"8038\" data-end=\"8160\"\u003eGhigo E. et al. Hexarelin and GHRP pharmacology and endocrine effects. \u003cem data-start=\"8109\" data-end=\"8157\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8161\" data-end=\"8257\"\u003e\n\u003cp data-start=\"8163\" data-end=\"8257\"\u003eBisi G. et al. Human GH responses to hexarelin vs other secretagogues. \u003cem data-start=\"8234\" data-end=\"8254\"\u003eNeuroendocrinology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8258\" data-end=\"8380\"\u003e\n\u003cp data-start=\"8260\" data-end=\"8380\"\u003eBodart V. et al. CD36-mediated cardiovascular actions of hexarelin. \u003cem data-start=\"8328\" data-end=\"8350\"\u003eCirculation Research\u003c\/em\u003e; \u003cem data-start=\"8352\" data-end=\"8377\"\u003eCardiovascular Research\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8381\" data-end=\"8510\"\u003e\n\u003cp data-start=\"8383\" data-end=\"8510\"\u003eTóth K. et al. Anti-remodelling and anti-apoptotic effects in cardiac injury. \u003cem data-start=\"8461\" data-end=\"8507\"\u003eJournal of Molecular and Cellular Cardiology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8511\" data-end=\"8611\"\u003e\n\u003cp data-start=\"8513\" data-end=\"8611\"\u003eCappello F. et al. Hexarelin and skeletal muscle preservation under unloading. \u003cem data-start=\"8592\" data-end=\"8608\"\u003eMuscle \u0026amp; Nerve\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8612\" data-end=\"8732\"\u003e\n\u003cp data-start=\"8614\" data-end=\"8732\"\u003eNagaya N. et al. Ghrelin\/secretagogues in heart failure and ischemia models. \u003cem data-start=\"8691\" data-end=\"8729\"\u003eAmerican Journal of Physiology–Heart\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8733\" data-end=\"8838\"\u003e\n\u003cp data-start=\"8735\" data-end=\"8838\"\u003eVirdis A. et al. Endothelial benefits and eNOS activation with GHSR agonism. \u003cem data-start=\"8812\" data-end=\"8835\"\u003eVascular Pharmacology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8839\" data-end=\"8946\"\u003e\n\u003cp data-start=\"8841\" data-end=\"8946\"\u003eMüller A. et al. Sleep architecture changes with GHS administration. \u003cem data-start=\"8910\" data-end=\"8943\"\u003eSleep; Psychoneuroendocrinology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8947\" data-end=\"9042\"\u003e\n\u003cp data-start=\"8949\" data-end=\"9042\"\u003eWorld Anti-Doping Agency. \u003cstrong data-start=\"8975\" data-end=\"8999\"\u003eProhibited List 2025\u003c\/strong\u003e — peptide hormones and related substances.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684853838162,"sku":null,"price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/hexarelin10mg.png?v=1770834869","url":"https:\/\/sciencepeptideslab.com\/products\/hexarelin-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}